Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation

National Drug Schedules (NDS) Updates - January 28, 2022

Final Recommendations for brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%

The interim recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on December 6, 2021 that:

  • Brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older be granted Schedule III status, subject to the removal from the Prescription Drug List (PDL)
  • Brimonidine or its salts, except when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older will remain in Schedule I (as per the Prescription Drug List)

were finalized effective January 25, 2022. Final approval of the interim recommendations was made by NAPRA’s Board of Directors, in consideration of comments received during the 30-day review period. The National Drug Schedules will be revised accordingly once the affected substance is  removed from the Prescription Drug List.